By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Momenta Pharmaceuticals, Inc. 

675 West Kendall Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-491-9700 Fax: 617-621-0431


Momenta is a leader in the analysis, characterization, and design of complex pharmaceutical products. Our scientific foundation is a set of tools and methods that enable one to develop a deep understanding of the links between a compound’s chemical structure, its manufacturing process and its biological function. We are applying our innovative technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.

Our success is a result of our committed and talented people. We attract scientists exceptionally skilled in integrating information from diverse technical disciplines and task them with challenging characterization, process, and biology problems. Using this approach, we have designed tools and methods to understand the structure (characterization of chemical components), structure-process (design and control of manufacturing process) and structure-activity (relationships between structure and biological and clinical activity) of complex mixture drugs. From this knowledge comes a diversified product development pipeline consisting of complex generics, biosimilars and novel drugs designed to address a variety of medical needs.

In April 2015, Momenta announced the FDA approval of once daily Glatopa™ (glatiramer acetate injection), a fully substitutable generic version of Copaxone® 20 mg/mL. Glatopa was developed under a collaboration agreement between Momenta and Sandoz and is the second complex generic developed by Momenta to receive FDA approval.

In July 2010, Momenta announced the FDA approval of our first drug, Enoxaparin Sodium Injection developed in collaboration with Sandoz.

Key Statistics

Ownership: Public

Web Site: Momenta
Employees: 270
Symbol: MNTA


Company News
Momenta (MNTA) Puts a Temporary Hold on Enrollment in Phase II Necuparanib Study to Discuss Specific Toxicities 11/13/2015 6:17:16 AM
Momenta (MNTA) To Webcast Presentation At The Credit Suisse 24th Annual Healthcare Conference 10/28/2015 10:15:54 AM
Momenta (MNTA) Announces Publication Of Two Glatopa (Glatiramer Acetate Injection) Manuscripts 10/26/2015 7:26:55 AM
Baxalta And Momenta (MNTA) Announce Initiation Of Pivotal Clinical Trial For M923, A Biosimilar Version Of HUMIRA (adalimumab) 10/5/2015 10:46:18 AM
Momenta (MNTA) Appoints Georges Gemayel, Ph.D., To Board Of Directors 9/18/2015 6:22:16 AM
Momenta (MNTA) To Webcast Presentation At The Morgan Stanley (MST) Global Healthcare Conference 9/3/2015 10:39:45 AM
Momenta (MNTA) Announces Date Of Second Quarter 2015 Financial Results Conference Call And Webcast 7/21/2015 7:28:48 AM
Momenta (MNTA) Announces CAFC Decision To Invalidate Remanded Teva (TEVA) Patent In Daily COPAXONE 20 Mg Suit 6/18/2015 11:14:39 AM
Momenta (MNTA) Announces Oral And Poster Presentations Relating To Novel Autoimmune Programs At EULAR 2015 6/4/2015 10:15:55 AM
ASCO15: Momenta (MNTA) To Present New Data From Phase 1 Trial Of Necuparanib In Patients With Pancreatic Cancer 6/1/2015 10:29:33 AM